Prognostic Value of Metabolic Information in Advanced Gastric Cancer Using Preoperative 18F-FDG PET/CT

Kwon, Ho Jang; Pahk, Kisoo; Kim, Sungeun

doi:10.1007/s13139-019-00622-w

Cited by 11 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SUV max strongly predicts not only lung cancer but also other types of cancers. It is important to mention multiple articles that focused on SUV max [ 18 F]FDG PET analysis in pretreated primary tumours for the prediction of the occurrence of neck metastasis in oral cancer 29 , head and neck squamous cell carcinoma 30 and others 31 , 32 . Despite strong evidence showing the scientific and medical value of SUV max , it should be noted that some other studies have revealed no correlation between SUV max and tumour recurrence 33 .…”

Section: Discussionmentioning

confidence: 99%

Differences among [18F]FDG PET-derived parameters in lung cancer produced by three software packages

Boś-Liedke

Cegła

Matuszewski

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Investigation of differences in derived [18F]FDG PET metabolic and volumetric parameters among three different software programs in lung cancer. A retrospective analysis was performed on a group of 98 lung cancer patients who underwent a baseline [18F]FDG PET/CT study. To assess appropriate delineation methods, the NEMA phantom study was first performed using the following software: Philips EBW (Extended Brilliance Workstation), MIM Software and Rover. Based on this study, the best cut-off methods (dependent on tumour size) were selected, extracted and applied for lung cancer delineation. Several semiquantitative [18F]FDG parameters (SUVmax, SUVmean, TLG and MTV) were assessed and compared among the three software programs. The parameters were assessed based on body weight (BW), lean body mass (LBM) and Bq/mL. Statistically significant differences were found in SUVmean (LBM) between MIM Software and Rover (4.62 ± 2.15 vs 4.84 ± 1.20; p < 0.005), in SUVmean (Bq/mL) between Rover and Philips EBW (21,852.30 ± 21,821.23 vs 19,274.81 ± 13,340.28; p < 0.005) and Rover and MIM Software (21,852.30 ± 21,821.23 vs 19,399.40 ± 10,051.30; p < 0.005), and in MTV between MIM Software and Philips EBW (19.87 ± 25.83 vs 78.82 ± 228.00; p = 0.0489). This study showed statistically significant differences in the estimation of semiquantitative parameters using three independent image analysis tools. These findings are important for performing further diagnostic and treatment procedures in lung cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Differences among [18F]FDG PET-derived parameters in lung cancer produced by three software packages

Boś-Liedke

Cegła

Matuszewski

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…A paradigm shift has occurred in the management of NSCLC as a result of recent success in the treatment of locally advanced and metastatic NSCLC with immunotherapy [ 77 , 78 , 79 , 80 ]. Some studies have reported finding inverse correlations between tumor glycolytic metabolism and/or FDG uptake and tumor infiltration by effector immune cells [ 81 , 82 , 83 ]. Mitchell et al reported identifying an association between elevated FDG retention and highly glycolytic metabolism, the expression of enhanced programmed death-ligand 1 (PD-L1), and an immunosuppressive phenotype in surgically resected NSCLCs [ 84 ].…”

Section: Correlation Between Fdg-pet/ct and Tumor Immunometabolic mentioning

confidence: 99%

Recent and Current Advances in FDG-PET Imaging within the Field of Clinical Oncology in NSCLC: A Review of the Literature

Kaseda¹

2020

Diagnostics

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related deaths around the world, the most common type of which is non-small-cell lung cancer (NSCLC). Computed tomography (CT) is required for patients with NSCLC, but often involves diagnostic issues and large intra- and interobserver variability. The anatomic data obtained using CT can be supplemented by the metabolic data obtained using fluorodeoxyglucose F 18 (FDG) positron emission tomography (PET); therefore, the use of FDG-PET/CT for staging NSCLC is recommended, as it provides more accuracy than either modality alone. Furthermore, FDG-PET/magnetic resonance imaging (MRI) provides useful information on metabolic activity and tumor cellularity, and has become increasingly popular. A number of studies have described FDG-PET/MRI as having a high diagnostic performance in NSCLC staging. Therefore, multidimensional functional imaging using FDG-PET/MRI is promising for evaluating the activity of the intratumoral environment. Radiomics is the quantitative extraction of imaging features from medical scans. The chief advantages of FDG-PET/CT radiomics are the ability to capture information beyond the capabilities of the human eye, non-invasiveness, the (virtually) real-time response, and full-field analysis of the lesion. This review summarizes the recent advances in FDG-PET imaging within the field of clinical oncology in NSCLC, with a focus on surgery and prognostication, and investigates the site-specific strengths and limitations of FDG-PET/CT. Overall, the goal of treatment for NSCLC is to provide the best opportunity for long-term survival; therefore, FDG-PET/CT is expected to play an increasingly important role in deciding the appropriate treatment for such patients.

show abstract

“…Fluorine-18-Fluorodeoxyglucose positron emission tomography/computed tomography ([18F]-FDG PET/CT) plays an important role in staging and treatment response assessment in various malignancies, including gastroesophageal cancer, providing significant diagnostic and prognostic value amongst these patients [ 7 , 8 , 9 ]. [18F]-FDG PET/CT provides various different standard metabolic parameters, including standardized uptake value (SUV), metabolic tumor volume (MTV) or total lesion glycolysis (TLG).…”

Section: Introductionmentioning

confidence: 99%

Prognostic Value of [18F]-FDG PET/CT Radiomics Combined with Sarcopenia Status among Patients with Advanced Gastroesophageal Cancer

Hinzpeter

Mirshahvalad

Kulanthaivelu

et al. 2022

Cancers

View full text Add to dashboard Cite

We investigated, whether 18[18F]-FDG PET/CT-derived radiomics combined with sarcopenia measurements improves survival prognostication among patients with advanced, metastatic gastroesophageal cancer. In our study, 128 consecutive patients with advanced, metastatic esophageal and gastroesophageal cancer (n = 128; 26 females; 102 males; mean age 63.5 ± 11.7 years; age range: 29–91 years) undergoing 18[18F]-FDG PET/CT for staging between November 2008 and December 2019 were included. Segmentation of the primary tumor and radiomics analysis derived from PET and CT images was performed semi-automatically with a commonly used open-source software platform (LIFEX, Version 6.30, lifexsoft.org). Patients’ nutritional status was determined by measuring the skeletal muscle index (SMI) at the level of L3 on the CT component. Univariable and multivariable analyses were performed to establish a survival prediction model including radiomics, clinical data, and SMI score. Univariable Cox proportional hazards model revealed ECOG (<0.001) and bone metastasis (p = 0.028) to be significant clinical parameters for overall survival (OS) and progression free survival (PFS). Age (p = 0.017) was an additional prognostic factor for OS. Multivariable analysis showed improved prognostication for overall and progression free survival when adding sarcopenic status, PET and CT radiomics to the model with clinical parameters only. PET and CT radiomics derived from hybrid 18[18F]-FDG PET/CT combined with sarcopenia measurements and clinical parameters may improve survival prediction among patients with advanced, metastatic gastroesophageal cancer.

show abstract

Prognostic Value of Metabolic Information in Advanced Gastric Cancer Using Preoperative 18F-FDG PET/CT

Cited by 11 publications

References 34 publications

Differences among [18F]FDG PET-derived parameters in lung cancer produced by three software packages

Differences among [18F]FDG PET-derived parameters in lung cancer produced by three software packages

Recent and Current Advances in FDG-PET Imaging within the Field of Clinical Oncology in NSCLC: A Review of the Literature

Prognostic Value of [18F]-FDG PET/CT Radiomics Combined with Sarcopenia Status among Patients with Advanced Gastroesophageal Cancer

Contact Info

Product

Resources

About